With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.224311-51-7,2-(Di-tert-Butylphosphino)biphenyl,as a common compound, the synthetic route is as follows.
Example 9 A mixture of 5-(3-bromophenoxy)isophthalonitrile (75 mg), 3-hydroxybenzotrifluoride (61 mg), palladium(II) acetate (11 mg), tripotassium phosphate (0.106 g) and 2-(di-tert-butylphosphino)biphenyl (18 mg) in dry toluene was heated at reflux under a nitrogen atmosphere for 24 hours. Water and ethyl acetate were added to the cooled mixture, followed by acidification with aqueous hydrochloric acid (2M). The phases were separated and the organic layer dried over magnesium sulphate, concentrated and purified by flash chromatography. Elution with 5percent ethyl acetate/i-hexane gave 5-[3-(3-trifluoromethylphenoxy)phenoxy]isophthalonitrile (Compound 77, 32 mg), NMR 7.62 (1H, s); 7.52-7.37 (5H, m); 7.31 (1H, s); 7.25 (1H, d); 6.92 (1H, dd); 6.82 (1H, dd); 6.73 (1H, t).
224311-51-7, As the paragraph descriping shows that 224311-51-7 is playing an increasingly important role.
Reference£º
Patent; Cornell, Clive; Cramp, Michael Colin; Gingell, Michael; Westaway, Susan; US2003/181334; (2003); A1;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate